½ÃÀ庸°í¼­
»óǰÄÚµå
1666711

eClinical ¼Ö·ç¼Ç ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

eClinical Solutions Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 145 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ eClinical ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â¿¡ 111¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2034³â¿¡ CAGR 12.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ±Þ¼ºÀåÀÇ ¹è°æ¿¡´Â µðÁöÅÐ ±â¼úÀ» Ȱ¿ëÇÏ¿© µ¥ÀÌÅÍ ¼öÁýÀ» È¿À²È­Çϰí ȯÀÚ Âü¿©¸¦ Çâ»ó½ÃŰ´Â ºÐ»êÇü ÀÓ»ó½ÃÇèÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ¿þ¾î·¯ºí ±â±â, ¸ð¹ÙÀÏ Çコ ¿ëµµ, ÀüÀڰǰ­±â·ÏÀÇ »ç¿ëÀÌ Áõ°¡Çϸ鼭 ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú µ¥ÀÌÅÍ Á¤È®µµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

e«¯«ê«Ë«««ë Solutions Market-IMG1

±ÔÁ¦±â°ü ¶ÇÇÑ ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» ÃÖÀûÈ­Çϰí ȯÀÚ ¾ÈÀü ±âÁØÀ» À¯ÁöÇϱâ À§ÇØ µðÁöÅÐ ÅøÀ» ¿ËÈ£Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á ¹× ¸¸¼ºÁúȯ Ä¡·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î Àü ¼¼°è¿¡¼­ ÀÓ»ó½ÃÇèÀÇ ¾çÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü eÀÓ»ó¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ȯÀÚ ¸ðÁý, ÄÄÇöóÀ̾𽺠¸ð´ÏÅ͸µ, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®°ú °°Àº º¹ÀâÇÑ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÏ¿© Á¡Á¡ ´õ º¹ÀâÇØÁö´Â ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀ» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ¿¬µµ 2024³â
¿¹Ãø¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 111¾ï ´Þ·¯
¿¹»ó ±Ý¾× 353¾ï ´Þ·¯
CAGR 12.1%

eÀÓ»ó¼Ö·ç¼Ç¿¡´Â ÀÓ»ó½ÃÇè °ü¸®¸¦ °£¼ÒÈ­Çϱâ À§ÇØ ¼³°èµÈ ÷´Ü ¼ÒÇÁÆ®¿þ¾î¿Í µðÁöÅÐ Ç÷§ÆûÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý(EDC) ½Ã½ºÅÛ, ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS), ÀüÀÚ È¯ÀÚ º¸°í °á°ú(ePRO) µî ¿©·¯ ¼Ò½ºÀÇ µ¥ÀÌÅ͸¦ ÅëÇÕÇÏ¿© Á¤È®¼ºÀ» ³ôÀÌ°í ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇϸç, EDC ºÐ¾ß´Â µ¥ÀÌÅÍ Ã³¸® °­È­, ¼öÀÛ¾÷ ¿À·ù ÃÖ¼ÒÈ­, ½Ç½Ã°£ ¸ð´ÏÅ͸µ °¡¼ÓÈ­ µîÀÇ ±â´ÉÀ» ÅëÇØ 2024³â±îÁö 25¾ï ´Þ·¯ ±Ô¸ð ½ÃÀåÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Ç½Ã°£ ¸ð´ÏÅ͸µ °¡¼ÓÈ­ µîÀÇ ±â´ÉÀ¸·Î 2024³â 25¾ï ´Þ·¯ ±Ô¸ð ½ÃÀåÀ» âÃâÇÏ¸ç ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀÌ º¹ÀâÇØÁü¿¡ µû¶ó ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

2024³â ½ÃÀå Á¡À¯À²Àº À¥È£½ºÆ®Çü ¼Ö·ç¼ÇÀÌ 50.9%·Î °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. È®À强, °æÁ¦¼º, µµÀÔ ¿ëÀ̼ºÀ¸·Î ÀÎÇØ ºÐ»êÇü ÀÓ»ó½ÃÇè¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ¿ø°Ý ¾×¼¼½º, ´Ù¸¥ µðÁöÅÐ Åø¿ÍÀÇ ¿øÈ°ÇÑ ÅëÇÕ, °­·ÂÇÑ º¸¾È ±â´ÉÀ» ÅëÇØ ±× º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½Ç½Ã°£ Çù¾÷°ú µ¥ÀÌÅÍ °øÀ¯¸¦ ÃËÁøÇÏ´Â ±â´ÉÀ» ÅëÇØ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó 3»ó ½ÃÇè ºÐ¾ß´Â 2024³â¿¡ ½ÃÀåÀ» Àå¾ÇÇϰí 2034³â¿¡´Â 151¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ´Ü°è¿¡¼­´Â Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡Çϱâ À§ÇÑ ´ë±Ô¸ð ½ÃÇèÀÌ ÁøÇàµÇ¹Ç·Î È¿À²ÀûÀÎ µ¥ÀÌÅÍ °ü¸®¿Í ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇϸç, eŬ¸®´ÏÄÃ ÅøÀº ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁýÀ» °¡´ÉÇÏ°Ô ÇÏ°í ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ÇÁ·Î¼¼½º¸¦ °­È­ÇÕ´Ï´Ù. °­È­ÇÕ´Ï´Ù.

ÀÓ»ó½ÃÇè ¼öʱâ°ü(CRO)Àº ¿¹Ãø ±â°£ Áß 12.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CROÀÇ Àü¹®¼º°ú È¿À²¼ºÀ¸·Î ÀÎÇØ Àӻ󿬱¸¸¦ CRO¿¡ À§Å¹ÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. À̵é Á¶Á÷Àº eÀÓ»ó¼Ö·ç¼ÇÀ» Ȱ¿ëÇÏ¿© º¹ÀâÇÑ ´Ù±¹°¡ÀÇ ÀÓ»ó½ÃÇèÀ» °ü¸®Çϰí, ¾÷¹«¸¦ °£¼ÒÈ­Çϸç, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» ½ÇÇöÇϱâ À§ÇØ eÀÓ»ó¼Ö·ç¼ÇÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹Àº 2024³â ºÏ¹Ì ½ÃÀåÀ» Àå¾ÇÇϰí CAGR 11.7%·Î ¼±µÎ¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¹Ì±¹ÀÇ ÅºÅºÇÑ Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷°ú ±â¼ú Çõ½Å ¹× ÀÓ»ó½ÃÇèÀÇ ºÐ»êÈ­¿¡ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÁÖ¿ä ¿¬±¸±â°ü°ú ±ÔÁ¦±â°üÀÇ Á¸Àç´Â ÷´Ü e-ÀÓ»ó±â¼úÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¾÷°è ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Á¤ºÎ º¸Á¶±ÝÀÇ Áõ°¡
      • CRO¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè ¾Æ¿ô¼Ò½ÌÀÇ ¼ö¿ä Áõ°¡
      • ÀÓ»ó½ÃÇè¿¡¼­ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÇ Ã¤Åà Áõ°¡
      • ¼¼°è¿¡¼­ ¿¬±¸°³¹ßºñÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¡¤°úÁ¦
      • ³ôÀº µµÀÔ ºñ¿ë
      • ½ÅÈï ±¹°¡¿¡¼­ eClinical ¼Ö·ç¼ÇÀÇ ³·Àº º¸±Þ·ü°ú ÀÎÁöµµ
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ¼ÒÇÁÆ®¿þ¾î »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ½ÃÀå ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¼Ö·ç¼Çº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ¹«ÀÛÀ§È­¿Í ÀÓ»ó½ÃÇè °ø±Þ °ü¸®
  • ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS)
  • ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS)
  • ÀüÀÚ ÀÓ»ó°á°úÆò°¡(eCOA)
  • ÀüÀÚ ÀÓ»ó½ÃÇè ¸¶½ºÅÍ ÆÄÀÏ(eTMF)
  • ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý(EDC)
  • ±âŸ ¼Ö·ç¼Ç

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : µô¸®¹ö¸® ¸ðµåº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ±â¾÷¿ë(¿ÂÇÁ·¹¹Ì½º) ¶óÀ̼±½Ì ¼Ö·ç¼Ç
  • Ŭ¶ó¿ìµå ±â¹Ý(SAAS) ¼Ö·ç¼Ç(CBS)
  • À¥ È£½ºÆ®Çü(¿Âµð¸Çµå) ¼Ö·ç¼Ç(WHS)

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÀÓ»ó½ÃÇè ´Ü°èº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ´Ü°è I
  • ´Ü°è II
  • ´Ü°è III
  • ´Ü°è IV

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • CRO(ÀÓ»ó½ÃÇè ¼öʱâ°ü ±â°ü)
  • ÀÇ·á±â±â ±â¾÷
  • Á¦¾à/¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • º´¿ø¡¤Å¬¸®´Ð
  • ±âŸ ÃÖÁ¾ ¿ëµµ

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • Æú¶õµå
    • ½ºÀ§½º
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ¾Æ¸£ÇîÆ¼³ª
    • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ÀÌÁýÆ®

Á¦10Àå ±â¾÷ °³¿ä

  • Acralyon
  • Anju Software(OmniComm System)
  • Bio-optronics
  • Clario
  • Dassault Systemes(Medidata)
  • Datatrak
  • Ennov
  • IBM
  • Medsharing
  • Multihealth Group(Clinfile)
  • OpenClinica
  • Oracle Corporation
  • Parexel International
  • Signant Health(CRF Health)
  • Veeva Systems
KSA 25.04.01

The Global EClinical Solutions Market, valued at USD 11.1 billion in 2024, is forecasted to grow at a CAGR of 12.1% from 2025 to 2034. This rapid growth is driven by the increasing adoption of decentralized clinical trials, which utilize digital technologies to streamline data collection and improve patient engagement. The rising use of wearable devices, mobile health applications, and electronic health records is enhancing real-time monitoring and data accuracy.

eClinical Solutions Market - IMG1

Regulatory bodies are also advocating for digital tools to optimize trial efficiency and maintain patient safety standards. Additionally, the escalating volume of clinical trials worldwide, fueled by advancements in personalized medicine and treatments for chronic conditions, is amplifying the need for advanced eClinical solutions. These platforms simplify complex processes such as patient recruitment, compliance monitoring, and real-time data analytics, making them essential in managing the growing intricacies of large-scale trials.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$11.1 Billion
Forecast Value$35.3 Billion
CAGR12.1%

eClinical solutions encompass advanced software and digital platforms designed to streamline clinical trial management. These tools integrate data from multiple sources, including electronic data capture (EDC) systems, clinical trial management systems (CTMS), and electronic patient-reported outcomes (ePRO), ensuring improved accuracy and regulatory compliance. The EDC segment led the market in 2024, generating USD 2.5 billion, due to its ability to enhance data processing, minimize manual errors, and accelerate real-time monitoring. As trials become more complex, the demand for such systems continues to rise.

Web-hosted solutions accounted for the largest market share of 50.9% in 2024. Their scalability, affordability, and ease of deployment make them ideal for decentralized trials. These solutions enable remote access, seamless integration with other digital tools, and robust security features, driving their widespread adoption. Their ability to facilitate real-time collaboration and data sharing has further solidified their market position.

The phase III clinical trial segment dominated the market in 2024, projected to reach USD 15.1 billion by 2034. This phase involves large-scale testing to evaluate treatment safety and efficacy, necessitating efficient data management and monitoring. eClinical tools enhance these processes by enabling real-time data capture and ensuring compliance with regulatory requirements.

Contract research organizations (CROs) are set to grow at a 12.5% CAGR over the forecast period. The rising trend of outsourcing clinical research to CROs, driven by their expertise and efficiency, is a key market driver. These organizations utilize eClinical solutions to manage complex multinational trials, streamline operations, and ensure real-time data analysis.

The US dominated the North American market in 2024 and is expected to maintain its lead with a CAGR of 11.7%. This is attributed to the country's robust pharmaceutical and biotechnology industries, as well as its emphasis on technological innovation and decentralized trials. The presence of major research institutions and regulatory bodies further supports the adoption of advanced eClinical technologies.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rise in government funding grants for clinical trials
      • 3.2.1.2 Growing demand for outsourcing clinical trials to CROs
      • 3.2.1.3 Increasing adoption of software solutions in clinical trials
      • 3.2.1.4 Increasing R&D expenditure across the globe
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High implantation cost
      • 3.2.2.2 Low adoption and lack of awareness pertaining to eClinical solutions in developing countries
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Software landscape
  • 3.6 Porter’s analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Solution, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Randomization and trial supply management
  • 5.3 Clinical data management system (CDMS)
  • 5.4 Clinical trial management system (CTMS)
  • 5.5 Electronic clinical outcome assessment (eCOA)
  • 5.6 Electronic trial master file (eTMF)
  • 5.7 Electronic data capture (EDC)
  • 5.8 Other solutions

Chapter 6 Market Estimates and Forecast, By Delivery Mode, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Licensed enterprise (on-premise) solutions
  • 6.3 Cloud-based (SAAS) solution (CBS)
  • 6.4 Web-hosted (on-demand) solution (WHS)

Chapter 7 Market Estimates and Forecast, By Clinical Trial Phase, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Phase I
  • 7.3 Phase II
  • 7.4 Phase III
  • 7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Contract research organizations (CROs)
  • 8.3 Medical device companies
  • 8.4 Pharma/biotech companies
  • 8.5 Hospitals and clinics
  • 8.6 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Poland
    • 9.3.7 Switzerland
    • 9.3.8 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Indonesia
    • 9.4.7 Thailand
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Argentina
    • 9.5.5 Chile
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Egypt

Chapter 10 Company Profiles

  • 10.1 Acralyon
  • 10.2 Anju Software (OmniComm System)
  • 10.3 Bio-optronics
  • 10.4 Clario
  • 10.5 Dassault Systemes (Medidata)
  • 10.6 Datatrak
  • 10.7 Ennov
  • 10.8 IBM
  • 10.9 Medsharing
  • 10.10 Multihealth Group (Clinfile)
  • 10.11 OpenClinica
  • 10.12 Oracle Corporation
  • 10.13 Parexel International
  • 10.14 Signant Health (CRF Health)
  • 10.15 Veeva Systems
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦